Acuta Capital Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Acuta Capital Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-32,500	Closed	-$3.61M	–	54
2020 Q4	$3.61M	Buy	+32,500	New	+$3.97M	0.98%	36
2018 Q4	–	Sell	-33,000	Closed	-$7.07M	–	29
2018 Q3	$7.07M	Sell	33,000 -1,803	-5%	-$452K	2.52%	13
2018 Q2	$9.73M	Buy	+34,803	New	+$6.11M	1.73%	14

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Acuta Capital Partners's MDGL Position: Q1 2021 in Review

Acuta Capital Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2021, closing a stake of 32,500 shares — an estimated $3.61M sold.

Acuta Capital Partners first reported a position in MDGL in Q2 2018 and held it in 3 quarters. The position peaked at $9.73M in Q2 2018. 137 funds tracked by Wall St. Rank hold MDGL as of Q1 2021.

Acuta Capital Partners reported no remaining Madrigal Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Acuta Capital Partners sold 32,500 Madrigal Pharmaceuticals shares in Q1 2021, an estimated $3.61M.
Acuta Capital Partners first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 3 quarters.
Acuta Capital Partners's Madrigal Pharmaceuticals position peaked at $9.73M in Q2 2018.
137 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2021.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.